T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 563-574

  Salerno, Elise P ^a   Olson, Walter C ^a   McSkimming, Chantel ^a   Shea, Sofia ^a   Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

cancer immunology; chemokine receptor; integrin; metastatic melanoma; tumor microenvironment

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HOMING RECEPTOR; INTEGRIN; INTEGRIN ALPHA2BETA2; INTEGRIN ALPHA4BETA7; INTEGRIN ALPHAEBETA7; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 4;

ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CELL MATURATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84887865311     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28391     Document Type: Article

References (49)

1. Mihm MC, Jr, Clemente CG, Cascinelli N,. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74: 43-7.
2. Bogunovic D, O'Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009; 106: 20429-34.
3. Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72: 1070-80.
4. DeNucci CC, Mitchell JS, Shimizu Y,. Integrin function in T-Cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit Rev Immunol 2009; 29: 87-109.
5. Kinashi T,. Overview of integrin signaling in the immune system. Meth Mol Biol 2012; 757: 261-78.
6. Rose DM, Alon R, Ginsberg MH,. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev 2007; 218: 126-34.
7. Sheasley-O'Neill SL, Brinkman CC, Ferguson AR, et al. Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells. J Immunol 2007; 178: 1512-22.
8. Ferguson AR, Engelhard VH,. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J Immunol 2010; 184: 4079-86.
9. Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-85.
10. Sasaki K, Zhu X, Vasquez C, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 2007; 67: 6451-8.
11. Jokai H, Marschalko M, Csomor J, et al. Tissue-specific homing of immune cells in malignant skin tumors. Pathol Oncol Res 2012; 18: 749-59.
12. Schaefer JT, Patterson JW, Deacon DH, et al. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med 2010; 8: 79-91.
13. Sallusto F, Geginat J, Lanzavecchia A,. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-63.
14. Lazarovits AI, Moscicki RA, Kurnick JT, et al. Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol 1984; 133: 1857-62.
15. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
16. Gajewski TF, Louahed J, Brichard VG,. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010; 16: 399-403.
17. Hsu DS, Kim MK, Balakumaran BS, et al. Immune signatures predict prognosis in localized cancer. Cancer Invest 2010; 28: 765-73.
18. Weiss GR, Grosh WW, Chianese-Bullock KA, et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011; 17: 7440-50.
19. Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138: 1429-40.
20. Franciszkiewicz K, Le Floc'h A, Jalil A, et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res 2009; 69: 6249-55.
21. Sigmundsdottir H, Butcher EC,. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008; 9: 981-7.
22. Weishaupt C, Munoz KN, Buzney E, et al. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007; 13: 2549-56.
23. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008; 205: 2221-34.
24. Piali L, Fichtel A, Terpe HJ, et al. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181: 811-6.
25. Sauty A, Colvin RA, Wagner L, et al. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol 2001; 167: 7084-93.
26. Meiser A, Mueller A, Wise EL, et al. The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. J Immunol 2008; 180: 6713-24.
27. Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010; 102: 1129-36.
28. Shi Q, Cox LA, Glenn J, et al. Molecular pathways mediating differential responses to lipopolysaccharide between human and baboon arterial endothelial cells. Clin Exp Pharmacol P 2010; 37: 178-84.
29. Lee MT, Hooper LC, Kump L, et al. Interferon-beta and adhesion molecules (E-selectin and s-intracellular adhesion motecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling. Clin Exp Immunol 2007; 147: 71-80.
30. Dengel LT, Norrod AG, Gregory BL, et al. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother 2010; 33: 965-74.
31. Anz D, Mueller W, Golic M, et al. CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int J Cancer 2011; 129: 2417-26.
32. Hadley GA, Bartlett ST, Via CS, et al. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL. J Immunol 1997; 159: 3748-56.
33. Gebhardt T, Whitney PG, Zaid A, et al. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 2011; 477: 216-9.
34. Chapman TJ, Topham DJ,. Identification of a unique population of tissue-memory CD4+ T cells in the airways after influenza infection that is dependent on the integrin VLA-1. J Immunol 2010; 184: 3841-9.
35. Ben-Horin S, Goldstein I, Koltakov A, et al. The effect of blockade of tumor necrosis factor alpha on VLA-1+ T-cells in rheumatoid arthritis patients. J Clin Immunol 2007; 27: 580-8.
36. Conrad C, Boyman O, Tonel G, et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007; 13: 836-42.
37. Tsunoda I, Terry EJ, Marble BJ, et al. Modulation of experimental autoimmune encephalomyelitis by VLA-2 blockade. Brain Pathol 2007; 17: 45-55.
38. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8: 379-85.
39. Ye SW, Wang Y, Valmori D, et al. Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content. J Clin Immunol 2006; 26: 447-56.
40. Hirata T, Osuga Y, Takamura M, et al. Recruitment of CCR6-Expressing Th17 Cells by CCL 20 Secreted from IL-1 beta-, TNF-alpha-, and IL-17A-Stimulated Endometriotic Stromal Cells. Endocrinology 2010; 151: 5468-76.
41. Yurchenko E, Tritt M, Hay V, et al. CCR5-dependent homing of naturally occurring CD4(+) regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med 2006; 203: 2451-60.
42. Baitsch L, Legat A, Barba L, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012; 7: e30852.
43. Fourcade J, Sun Z, Pagliano O, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012; 72: 887-96.
44. Fourcade J, Kudela P, Sun Z, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009; 182: 5240-9.
45. Fourcade J, Kudela P, Sun ZJ, et al. PD-1 Is a Regulator of NY-ESO-1-Specific CD8(+) T Cell Expansion in Melanoma Patients. J Immunol 2009; 182: 5240-9.
46. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213-9.
47. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-94.
48. Ribas A, Comin-Anduix B, Economou JS, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 2009; 15: 390-9.
49. Peng W, Liu C, Xu C, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012; 72: 5209-18.